Antitrust Law Daily Wrap Up, ADVERTISING—S.D.N.Y.: ‘Comprehensive nutrition’ supplement label challenge dismissed, (May 20, 2026)

By Patricia K. Ruiz, J.D.

The court deemed most of the challenged statements non-actionable puffery or ambiguous but granted limited leave to amend GLP-1–targeted advertising claims.

The court granted a motion to dismiss by Grüns Nutrition Inc. in a putative consumer class action alleging that its “superfood greens gummies” were deceptively marketed as providing “comprehensive” and “complete” nutrition. It held that the challenged statements were either non-actionable puffery or, at most, ambiguous and clarified by product labeling and context, defeating claims under New York and California consumer protection statutes. The court allowed limited leave to amend only as to certain advertisements targeting GLP-1 medication users, finding plaintiffs failed to plead with sufficient specificity that those representations were actually false or misleading (Cavallaro-Kearins v. Grüns Nutrition, Inc., No. 1:25-cv-04998-LJL (S.D.N.Y. May 19, 2026)).

Background. Plaintiffs alleged that Grüns marketed its adult and children’s gummy supplements as a “comprehensive,” “all-in-one” nutritional solution capable of replacing dietary needs, fruits and vegetables, and other supplements. They claimed the products lacked essential nutrients such as protein, fats, calcium, and omega-3 fatty acids, and did not deliver the benefits advertised, including digestive health and energy improvements.

The complaint asserted violations of New York General Business Law §§ 349 and 350, California’s UCL, FAL, and CLRA, as well as common law fraud and unjust enrichment. Plaintiffs contended that consumers paid a price premium based on allegedly false representations of “comprehensive nutrition.”

“Comprehensive nutrition” deemed puffery or non-misleading. The court concluded that the central representation—that the gummies provided “comprehensive nutrition”—was not actionable. Read literally, the statement would imply that a consumer could obtain all necessary nutrition solely from the gummies, which the court found “plainly hyperbolic” and not something a reasonable consumer would believe.

To the extent plaintiffs urged a narrower interpretation—that “comprehensive” meant covering essential nutrients or replacing supplements—the court found the phrase ambiguous. Under governing standards, such ambiguity requires considering the label as a whole, including clarifying information on the back panel. Here, the product labeling disclosed nutrient contents and omissions, including the absence of protein, fat, calcium, and omega-3 fatty acids, making it unreasonable to interpret the front label as representing otherwise. The court held that these disclosures “definitively dispel” any arguable ambiguity created by the front-label statements.

Advertising context and additional statements. The court rejected plaintiffs’ reliance on broader marketing context, including website, social media, and email statements. Many of those statements repeated the same “comprehensive” language or consisted of non-specific claims about benefits and ingredients, which the court characterized as puffery or not alleged to be false. More specific statements regarding health benefits—such as improved immunity or testosterone—did not support the claims because plaintiffs failed to allege reliance on them or tie them to the asserted price premium theory. Similarly, child-focused marketing statements were found either ambiguous or clarified by surrounding information identifying specific ingredients and nutrient levels, defeating any plausible inference that the products could replace a complete diet.

GLP-1–targeted advertisements. The court identified a narrower category of potentially actionable statements directed at consumers using GLP-1 medications. Certain advertisements suggested the gummies could fill nutritional “gaps” created by such medications or provide “all nutrients” needed while using them. Unlike the broader “comprehensive nutrition” claims, these targeted statements could plausibly be interpreted as making specific, testable representations about the nutritional needs of GLP-1 users and the product’s ability to address them. However, the court held that plaintiffs failed to plead that the statements were actually false or misleading. The complaint did not identify what specific nutritional deficiencies GLP-1 users experience or how the gummies fail to address them, instead offering conclusory assertions. As a result, those claims were dismissed without prejudice.

Statutory claims. Applying the same “reasonable consumer” standard, the court dismissed claims under California’s UCL, FAL, and CLRA for the same reasons as the New York statutory claims. The court also emphasized that the California claims required reliance and, in some instances, heightened pleading under Rule 9(b), which plaintiffs did not satisfy.

Common law fraud and unjust enrichment. The court dismissed the common law fraud claims with prejudice, finding plaintiffs failed to plead scienter with the required specificity. Allegations that the defendant knew its statements were false or sought to increase sales were insufficient without particularized facts supporting fraudulent intent. The unjust enrichment claim was also dismissed with prejudice as duplicative of the statutory claims. Because it relied on the same alleged misrepresentations and injury theory, it could not proceed independently.

The Case is No. 1:25-cv-04998-LJL.

Judge: Liman, L.

Attorneys: Finnuala K. Tessier (Zimmerman Reed, LLP) for Patricia Cavallaro. William Cole (Amin Wasserman Gurnani, LLP) for Gruns Nutrition, Inc.

Companies: Gruns Nutrition, Inc.

Cases: Advertising StateUnfairTradePractices NewYorkNews